On April 4, 2023 Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) reported it will host an R&D Day focusing on new clinical results and biomarker data for its lead asset, the IL1RAP-binding antibody nadunolimab (CAN04), in pancreatic cancer (PDAC) patients, following presentation of these results at the AACR (Free AACR Whitepaper) Annual Meeting 2023 (AACR 2023) (Press release, Cantargia, APR 4, 2023, View Source [SID1234629820]). The R&D Day will be hosted by Cantargia management and Prof. Eric Van Cutsem, principal investigator in the CANFOUR trial.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Cantargia recently announced new results from the phase I/IIa clinical trial CANFOUR, evaluating nadunolimab in combination with chemotherapy for treatment of PDAC, to be presented at AACR (Free AACR Whitepaper) 2023 on April 17, 2023. A key finding is that patients with high tumor levels of IL1RAP, the target of nadunolimab, benefit most from the treatment.
During the R&D Day, Prof. Van Cutsem, Division Head of Digestive Oncology at University of Leuven and University Hospitals Gasthuisberg in Leuven, Belgium, and renowned expert in PDAC, will discuss the current treatment landscape in PDAC and the relevance of the new nadunolimab data. He will be joined by Dr. Dominique Tersago and Dr. David Liberg from Cantargia’s management team.
Event details and registration information
Date and time: April 24, 2023 2:00-3:30 PM CET (8:00-9:30 AM EST).
Venue: Redeye, Mäster Samuelsgatan 42, 10 tr, Stockholm
The event will be conducted in English and a simultaneous live webcast will be available for those unable to attend in person at the following link. The webcast will also be accessible on-demand, shortly after the event, at Cantargia’s website www.cantargia.com. A live question and answer session will follow the formal presentations. Participation in the event on-site requires registration at the following link.
Program
Welcome and introduction to Cantargia – Göran Forsberg, CEO
Nadunolimab mechanism of action – David Liberg, VP Research
Clinical results including new biomarker data of nadunolimab – Dominique Tersago, CMO
Pancreatic cancer and relevance of nadunolimab results – Prof. Eric Van Cutsem
Cantargia’s ongoing clinical trials – Dominique Tersago
Upcoming milestones and concluding remarks – Göran Forsberg
For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: [email protected]
The information was submitted for publication, through the agency of the contact person set out above, at 12.30 CET on 4 April 2023.